IRELAND Version 1.0

Pomalidomide Rowex (pomalidomide)

Event-Specific Questionnaire for HCP - Pregnancy Outcome Form(Patient or Partner of Patient)

This form must be returned to Rowex Ltd. Medical Information Tel: 027-50077 - Email: pv@rowa-pharma.ie

NOTE: Please use the first three letters of the month (e.g. JAN)

Reporter information				
Reporter Name:				
Address:				
City, County, Country:				
Phone No.:				
Fax No.:				
Patient information				
Patient ID: Date	of Birth:	D D M	O N Y Y Y	Ethnicity: White African-Caribbean Other, specify below
Partner of patient informat	ion			
○ Notapplicable				Ethnicity: White African-Caribbean Other, specify below
Pregnancy outcome				
Date of delivery: D D M	O N Y	YYYY	Gestation age	at delivery:
Normal	O No	O Yes		
C-section	O No	O Yes		
Induced	O No	O Yes		
Ectopic pregnancy	O No	O Yes		
Elective termination	O No	O Yes	Date:	D D M O N Y Y Y
Spontaneous abortion (≤20 weeks)	O No	O Yes	Weeks from LM	P:
Foetal death/stillbirth (>20 weeks)	-	O Yes		
Were the products of conception examined?	○ No	O Yes	If yes, was the foetus	normal? O No O Yes O Unknown Ifno, describe below
Obstetrics information				
Complications during pregnancy	O No	O Yes	If yes, please speci	fy
Complications during labour/deliver		O Yes	If yes, please specify	
Post-partum maternal complication			If yes, please specify	
Foetal outcome			, , ,	
Live normal infant	O No	O Yes		
Foetaldistress	O No	O Yes		
Intra-uterine growth retardation	O No			
Neonatal complication		○ Yes	If yes, please specify	
Birth defect noted?	O No	O Yes	If yes, please specify	
Sex: O Male O Female Bi	rthweigh	t:lbs_	oz. orke	Length:inches orcm.
Apgar score: 1min:5 min:	1	.0 min:	O Unknown	
Signature of person comple	ting this	form		
Signature:			Date	E D D M O N Y Y Y Y

IRELANDVersion 1.0

Pomalidomide Rowex (pomalidomide)

Event-Specific Questionnaire for HCP - Pregnancy Outcome Form(Patient or Partner of Patient)

This form must be returned to Rowex Ltd. Medical Information Tel: 027-50077 - Email: pv@rowa-pharma.ie

Drug Safety Data Privacy notice

Your personal data will be processed by Rowex Ltd. for the purposes of complying with its drug safety legal obligations and for storage purposes.

Rowex Ltd. may share your data with other Rowex Ltd. entities and third parties providing services to Rowex Ltd. This may entail the transfer of your data to other countries such as the USA and India. When such countries do not provide an equivalent level of protection to personal data as your country, Rowex Ltd. will implement appropriate legal, organisational, and technical security measures to protect your information from unauthorised access, use or disclosure, including the use of standard data protection clauses and Binding Corporate Rules. Rowex Ltd. will retain your personal data for the length of time required by law.

You have the right to access and verify your personal information held by Rowex Ltd., receive a copy of it, obtain its correction and deletion if it is inaccurate and object to certain processing.

For the exercise of your rights and for any questions regarding data protection you can contact us at pv@rowa-pharma.ie. If you are unhappy about how Rowex Ltd. is processing your personal data, you have the right to lodge a complaint with the supervisory authority.

Reporter's Signature (required):							
Signature:	Date signed:	D D M O N Y Y Y Y					

On behalf of Rowex Ltd., thank you for providing information that will assist us in our commitment to patient safety.



Date of preparation of text: February 2025 Approved by HPRA: March 2025